Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Short Interest Update

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) was the target of a large decrease in short interest in January. As of January 31st, there was short interest totalling 642,400 shares, a decrease of 55.7% from the January 15th total of 1,450,700 shares. Based on an average daily volume of 100 shares, the short-interest ratio is presently 6,424.0 days.

Analyst Ratings Changes

Separately, Barclays raised Swedish Orphan Biovitrum AB (publ) to a “strong-buy” rating in a report on Wednesday, January 8th.

Swedish Orphan Biovitrum AB (publ) Stock Performance

BIOVF remained flat at $30.48 on Friday. Swedish Orphan Biovitrum AB has a 1 year low of $22.87 and a 1 year high of $32.25. The business has a fifty day simple moving average of $28.68 and a 200-day simple moving average of $28.81. The company has a debt-to-equity ratio of 0.30, a current ratio of 0.73 and a quick ratio of 0.49. The stock has a market capitalization of $10.85 billion, a PE ratio of 51.66 and a beta of 0.53.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.